SteelPeak Wealth LLC Has $6.24 Million Stake in Pfizer Inc. $PFE

SteelPeak Wealth LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 16.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 257,256 shares of the biopharmaceutical company’s stock after purchasing an additional 36,195 shares during the quarter. SteelPeak Wealth LLC’s holdings in Pfizer were worth $6,236,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.45 on Tuesday. The company has a 50 day simple moving average of $24.72 and a 200 day simple moving average of $24.12. The stock has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.